Mizuho lowered the firm’s price target on Haemonetics (HAE) to $90 from $115 and keeps an Outperform rating on the shares post the earnings ...
BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...
Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per ...
Get Our Latest Stock Report on HAE Haemonetics Stock Performance Shares of Haemonetics stock opened at $66.15 on Monday. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt ...